Hopstem Biotechnology
Latest round
- Series C
Last raised
- Aug 2026
Total raised
- $87M
Investors
- 12
About Hopstem Biotechnology
, trading as Hopstem Biotechnology, operates as a nerve and stem cells developer that focuses on the diagnosis and research of nervous system disease. The company focuses on stem cell therapy for neurological diseases. At the same time, the company provides a variety of innovative scientific research products and services, including high-maturity human nerve cells and internationally leading brain organ products, as well as iPSC reprogramming, clinical-grade iPSC directed differentiation cell product joint development and authorization, and human in vitro disease models, drug screening, neurotoxicity testing, etc. The company's revenue is generated by providing high-quality human neural cells, 3D brain organoids, supporting stem cell culture and neural differentiation and maturation reagents, and technical services including gene editing.
Who invested in Hopstem Biotechnology
12 investors across 6 rounds
See all investors in Hopstem Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hopstem Biotechnology
Who invested in Hopstem Biotechnology?
Hopstem Biotechnology has 12 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hopstem Biotechnology raised?
Hopstem Biotechnology has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Hopstem Biotechnology last raise money?
Hopstem Biotechnology's most recent round on record is a Series C, in Aug 2026.
What does Hopstem Biotechnology do?
, trading as Hopstem Biotechnology, operates as a nerve and stem cells developer that focuses on the diagnosis and research of nervous system disease.
Where is Hopstem Biotechnology headquartered?
Hopstem Biotechnology is headquartered in Hangzhou, China.
Which VCs invest in companies like Hopstem Biotechnology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Hopstem Biotechnology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Hopstem Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.